Novartis loses Indian Glivec case
This article was originally published in Scrip
Executive Summary
India's Supreme Court has dismissed Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law.